Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2023-10-23
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD
NCT01663337
Neurobiological Responses in Alcoholism and Early Trauma
NCT04128228
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
NCT05223829
The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
NCT00896038
The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD
NCT02469259
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alcohol
Participants will drink beverages containing alcohol.
Alcohol
Participants will consume beverages containing alcohol.
Placebo
Participants will drink beverages containing a very low dose of alcohol (placebo condition).
Placebo
Participants will consume beverages containing a very low dose of alcohol (placebo condition).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alcohol
Participants will consume beverages containing alcohol.
Placebo
Participants will consume beverages containing a very low dose of alcohol (placebo condition).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* having consumed at least 4 (men) or 3 (women) drinks on at least two occasions over the last year
\- Meeting diagnostic criteria for PTSD, confirmed by structured interview
Exclusion Criteria
* neurologic abnormality including significant head trauma (loss of consciousness of ≥5-min)
* full Scale IQ \<85
* contraindication to MRI scanning
* positive pregnancy test
* severe alcohol use disorder
* current severe cannabis use disorder
* any current substance use disorder (other than alcohol, cannabis, or nicotine)
* scores \> 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone screen)
* ever being in an abstinence-oriented treatment program for alcohol use
* reporting wanting to quit drinking but not being able to
* any medical, religious, or other reasons for not drinking alcohol
* history of heart attack, heart trouble, high blood pressure, diabetes, or liver disease
* an adverse reaction to alcoholic beverages
* reporting never consuming 4 (men) or 3 (women) or more drinks on at least two occasions over the last year
* unwillingness to have a friend or family member drive them home after the alcohol administration sessions
* not taking medications for \>4 weeks (i.e. participants must be stable on meds)
* acute suicidality with intent
\- history of PTSD
* any prior psychiatric hospitalizations
* lifetime history of a neurodevelopmental disorder, affective disorder, psychotic disorder, suicide attempt, or eating disorder
* greater than 1 month of lifetime psychotropic medication
21 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas at Austin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elizabeth Thomas Cox Lippard
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elizabeth Lippard, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Austin
Josh Cisler, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Austin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas at Austin
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.